SG11201807402PA - Compositions - Google Patents

Compositions

Info

Publication number
SG11201807402PA
SG11201807402PA SG11201807402PA SG11201807402PA SG11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA SG 11201807402P A SG11201807402P A SG 11201807402PA
Authority
SG
Singapore
Prior art keywords
cambridge
vhsquared
copley
cambridgeshire
court
Prior art date
Application number
SG11201807402PA
Inventor
Scott Crowe
Mike West
Kevin Roberts
Tim Carlton
Luana Maggiore
Marion Cubitt
Gary Whale
John Wahlich
Mike Frodsham
Original Assignee
Vhsquared Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vhsquared Ltd filed Critical Vhsquared Ltd
Publication of SG11201807402PA publication Critical patent/SG11201807402PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111 10111 0111 100111111101 11101111111110111 OE 1111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/167997 Al 5 October 2017 (05.10.2017) WIP0 I PCT (51) International Patent Classification: ness Park, Cambridge Road, Cambridge Cambridgeshire A61K 9/14 (2006.01) A61K 9/20 (2006.01) CB22 3GN (GB). FRODSHAM, Mike; c/o Quay Pharma- A61K 38/00 (2006.01) A61K 9/50 (2006.01) ceuticals Limited, Quay House 28 Parkway, Deeside Indus - A61K 9/16 (2006.01) A61K 31/00 (2006.01) trial Park, Deeside Clwyd CH5 2NS (GB). (21) International Application Number: (74) Agents: RUSCOE, Peter et al.; Sagittarius IP, Three PCT/EP2017/057775 Globeside, Fieldhouse Lane, Marlow Buckinghamshire SL7 1HZ (GB). (22) International Filing Date: 31 March 2017 (31.03.2017) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, DO, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, 16163178.3 31 March 2016 (31.03.2016) EP KP, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: VHSQUARED LIMITED [GB/GB]; 1 Lower MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Court, Copley Hill Business Park, Cambridge Road, Bab- NI, NO, raham, Cambridge Cambridgeshire CB22 3GN (GB). RU, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (72) Inventors: CROWE, Scott; c/o VHsquared, 1 Lower ZA, ZM, ZW. Court, Copley Hill Business Park, Cambridge Road, Cam- _ bridge Cambridgeshire CB22 3GN (GB). WEST, Mike; (84) Designated States (unless otherwise indicated, for every c/o VHsquared, 1 Lower Court, Copley Hill Business Park, kind Cambridge Road, Cambridge Cambridgeshire CB22 3GN GM, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, — _ (GB). ROBERTS, Kevin; c/o VHsquared, 1 Lower Court, TZ, rt, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Copley Hill Business Park, Cambridge Road, Cambridge TJ, TM), Cambridgeshire CB22 3GN (GB). CARLTON, Tim; c/o DK, European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, = VHsquared, 1 Lower Court, Copley Hill Business Park, LV, Cambridge Road, Cambridge Cambridgeshire CB22 3GN SM, (GB). MAGGIORE, Luana; c/o VHsquared, 1 Lower GW, KM, ML, MR, NE, SN, TD, TG). Court, Copley Hill Business Park, Cambridge Road, Cam- Published: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, = — bridge Cambridgeshire CB22 3GN (GB). CUBITT, Mari- - on; c/o VHsquared, 1 Lower Court, Copley Hill Business with international search report (Art. 21(3)) = Park, Cambridge Road, Cambridge Cambridgeshire CB22 — with sequence listing part of description (Rule 5.2(a)) = 3GN (GB). WHALE, Gary; c/o VHsquared, 1 Lower with information concerning incorporation by reference of Court, Copley Hill Business Park, Cambridge Road, Cam- missing parts and/or elements (Rule 20.6) bridge Cambridgeshire CB22 3GN (GB). WAHLICH, John; c/o VHsquared, 1 Lower Court, Copley Hill Busi- _ = = = = = Il IN C:r C:r IN 1-1 IN 1-1 © (54) Title: COMPOSITIONS ei r .-. ) (57) : There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active '° binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a phar - .,- maceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
SG11201807402PA 2016-03-31 2017-03-31 Compositions SG11201807402PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163178 2016-03-31
PCT/EP2017/057775 WO2017167997A1 (en) 2016-03-31 2017-03-31 Compositions

Publications (1)

Publication Number Publication Date
SG11201807402PA true SG11201807402PA (en) 2018-09-27

Family

ID=55646428

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807402PA SG11201807402PA (en) 2016-03-31 2017-03-31 Compositions

Country Status (10)

Country Link
US (2) US10772839B2 (en)
EP (1) EP3435982A1 (en)
JP (2) JP7224917B2 (en)
KR (1) KR102376369B1 (en)
CN (2) CN109152738B (en)
AU (2) AU2017240190A1 (en)
CA (2) CA3019482A1 (en)
IL (1) IL261792B (en)
SG (1) SG11201807402PA (en)
WO (2) WO2017167997A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249144B2 (en) * 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
KR102622281B1 (en) * 2015-03-31 2024-01-08 소리소 파마슈티컬스 인크. polypeptide
EP3435982A1 (en) 2016-03-31 2019-02-06 VHsquared Limited Compositions
WO2018060453A1 (en) * 2016-09-30 2018-04-05 Vhsquared Limited Compositions
WO2018112240A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN116726361A (en) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 Methods and devices for treating diseases with biologic therapeutic agents
WO2020243393A1 (en) * 2019-05-30 2020-12-03 Vta Labs, Llc Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021233296A1 (en) * 2020-05-18 2021-11-25 深圳市塔吉瑞生物医药有限公司 Solid form of macrocyclic compound, preparation therefor and use thereof
CN113768051B (en) * 2020-06-09 2024-03-19 中粮营养健康研究院有限公司 Feed additive, preparation method thereof, application of feed additive in feed and tianti feed

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010126A (en) 1934-03-19 1935-08-06 Frank L Mclaughlin Measuring and dispensing can
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
ATE234855T1 (en) * 1993-09-20 2003-04-15 Anadis Ltd METHOD FOR PRODUCING IMMUNOGLOBULINS FROM COLOSTRUM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
BRPI0516681A (en) * 2004-11-25 2008-09-16 Unilever Nv antibody delivery system to the gastrointestinal tract, expression vector, transformed microorganisms, antibody delivery method, heavy chain immunoglobulins and their use, food product and its method of manufacture and delivery tool
ES2776657T3 (en) 2005-06-14 2020-07-31 Amgen Inc Self-buffering protein formulations
RU2009113557A (en) 2006-09-12 2010-10-20 Космо Текнолоджиз Лтд (Ie) PHARMACEUTICAL COMPOSITIONS FOR ORAL OR RECTAL INTRODUCTION OF PROTEIN SUBSTANCES
KR20090060453A (en) 2006-09-25 2009-06-12 메디뮨 엘엘씨 Stabilized antibody formulations and uses thereof
US20080145420A1 (en) * 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
PL2079445T3 (en) * 2007-02-20 2016-04-29 Allergan Pharmaceuticals Int Ltd Stable digestive enzyme compositions
CA2683415C (en) * 2007-04-04 2020-12-08 Sigmoid Pharma Limited An oral pharmaceutical composition
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2009037264A2 (en) 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
PL3354276T3 (en) 2007-11-13 2020-09-21 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
KR101581986B1 (en) 2008-10-29 2016-01-04 아블린쓰 엔.브이. Formulations of single domain antigen binding molecules
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN101964403A (en) 2009-07-23 2011-02-02 比克国际(天津)有限公司 Packaging method for battery pack and battery pack
US20130012916A1 (en) 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
WO2011109365A2 (en) 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
CA2792862C (en) 2010-03-10 2018-03-06 Incube Labs, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
BR112014028600B1 (en) 2012-05-18 2022-11-22 Genentech, Inc SUSPENSION FORMULATIONS COMPRISING HIGH CONCENTRATION MONOCLONAL ANTIBODY, ITS METHOD OF PREPARATION, ITS USE AND DEVICE FOR SUBCUTANEOUS ADMINISTRATION, AND METHOD FOR PRODUCING AN ARTICLE OF MANUFACTURING
CN104884089A (en) * 2012-08-21 2015-09-02 葛兰素集团有限公司 Compositions comprising a single variable domain and camostat mesylate (CM)
SG11201506499YA (en) 2013-03-15 2015-09-29 Glaxosmithkline Ip No 2 Ltd Low concentration antibody formulations
US20160228371A1 (en) 2013-10-18 2016-08-11 Abbvie Inc. Stable solid units and methods of making the same
US10220076B2 (en) * 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
KR102622281B1 (en) * 2015-03-31 2024-01-08 소리소 파마슈티컬스 인크. polypeptide
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3435982A1 (en) 2016-03-31 2019-02-06 VHsquared Limited Compositions

Also Published As

Publication number Publication date
US10980748B2 (en) 2021-04-20
AU2017240190A1 (en) 2018-09-20
CN109152738A (en) 2019-01-04
CN109152738B (en) 2023-10-13
AU2023200377A1 (en) 2023-02-23
CA3053757A1 (en) 2017-10-05
US20190008778A1 (en) 2019-01-10
EP3435982A1 (en) 2019-02-06
JP2023058591A (en) 2023-04-25
US10772839B2 (en) 2020-09-15
CA3019482A1 (en) 2017-10-05
WO2017171535A3 (en) 2017-12-07
KR20190003493A (en) 2019-01-09
WO2017171535A8 (en) 2017-11-16
KR102376369B1 (en) 2022-03-18
IL261792B (en) 2022-06-01
US20200368167A1 (en) 2020-11-26
WO2017167997A1 (en) 2017-10-05
JP7224917B2 (en) 2023-02-20
JP2019514855A (en) 2019-06-06
WO2017171535A2 (en) 2017-10-05
IL261792A (en) 2018-10-31
CN117243904A (en) 2023-12-19

Similar Documents

Publication Publication Date Title
SG11201807402PA (en) Compositions
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201804934PA (en) Novel Compounds
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11201808799SA (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201805072PA (en) Nicotine powder delivery system
SG11201810602YA (en) Method of treating liver fibrosis
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201806270XA (en) Gene therapy for treating mucopolysaccharidosis type i
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201907023UA (en) Method of reducing neutropenia
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809594WA (en) Nicotine particles and compositions
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers